Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 IMC-3G3 in previously treated unresectable or metastatic GIST
2010-022560-12Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaratumab in gastrointestinal stromal tumor (GIST) (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Tumor response rate of stable disease or better at 12 weeks. Started Apr 2011; status: completed.
02
Drugs
olaratumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2010-022560-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022560-12.